Actively Recruiting
Evaluate the Effects of Citicoline on Mood in Healthy Adults
Led by Kirin Holdings Company, Limited · Updated on 2025-09-02
90
Participants Needed
1
Research Sites
34 weeks
Total Duration
On this page
Sponsors
K
Kirin Holdings Company, Limited
Lead Sponsor
T
The Center for Applied Health Sciences, LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of this trial is to determine the effects of citicoline on mood in healthy Men and Women compared to a placebo.
CONDITIONS
Official Title
Evaluate the Effects of Citicoline on Mood in Healthy Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide voluntary signed and dated informed consent.
- Be in good health and able to participate as determined by medical history and routine blood chemistries.
- Biological men and women between 21 and 65 years of age (inclusive).
- Body Mass Index of 18.5-32.0 (inclusive).
- Body weight of at least 110 pounds.
- Participant is experiencing moderate levels of mood disturbance during screening.
- Normotensive (seated, resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg.
- Normal supine, resting heart rate (<90 per minute).
- Agrees to maintain their existing dietary and physical activity patterns throughout the study period.
- Participants agree to maintain their usual caffeine consumption habits, given that they do not exceed the maximum intake per day (400mg/day or 3-4 cups of coffee per day).
- If a dietary supplement was initiated within the past month, the participant is willing to discontinue supplement use followed by a 2-week washout prior to participation in the study.
- Willing to duplicate their previous 24-hour diet, refrain from caffeine for 24 hours, refrain from alcohol and exercise for 24 hours prior to each trial, and fast for 10 hours prior to each visit.
You will not qualify if you...
- QIDS (Quick Inventory of Depressive Symptomology) score > 16.
- Women who are pregnant, lactating, or planning to become pregnant during the study. Women must have a negative pregnancy test at screening.
- Women with a PSST (Premenstrual Symptoms Screening Tool) score 630
- Current smokers or cessation within 3 months prior to screening.
- Alcohol consumption (>2 standard alcoholic drinks/day or >10 drinks/week) or drug abuse/dependence.
- Current use of any nootropic dietary supplements (e.g., GABA, Ashwaghanda, St. John's Wort, Ginkgo biloba, L-theanine, choline, Lion's mane, creatine, etc.) or medications (e.g., piracetam, Adderall, modafinil, etc.) that may confound the study or its endpoints.
- Medical history of hepatorenal, musculoskeletal, autoimmune, or neurologic disease.
- Individuals who have been diagnosed with digestive, liver, renal, cardiovascular, or other metabolic diseases.
- Other known gastrointestinal or metabolic diseases that might impact nutrient absorption, distribution, metabolism, or excretion (e.g., intestinal malabsorption, electrolyte abnormalities, diabetes, thyroid disease, adrenal disease, hypogonadism, short bowel syndrome, diarrheal illnesses, history of colon resection, gastric ulcer, reflux disease, gastroparesis, Inborn-Errors-of-Metabolism, etc.).
- Chronic medically diagnosed inflammatory condition or disease (e.g., rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.).
- Medical history of a cognitive (i.e., ADD/ADHD) or psychiatric disorder, or brain-related medical conditions (e.g., TBI, ADHD).
- Currently using medications to treat anxiety or depression.
- Have an irregular sleep pattern (i.e. shift workers) or inadequate sleep schedule (i.e., less than 6 hours per night).
- Known sensitivity, allergy, or intolerability to any ingredient in the test products.
- Participants who report a clinically significant illness within the last 30 days.
- Individuals who are cognitively impaired and/or who are unable to give informed consent.
- Any other diseases or conditions that, in the opinion of the Principal Investigator, could confound the primary endpoint or place the subject at increased risk of harm if they were to participate.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Center for Applied Health Sciences
Canfield, Ohio, United States, 44406
Actively Recruiting
Research Team
T
Tim Ziegenfuss, Ph.D., CSCS, FISSN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here